Lv4
660 积分 2023-10-18 加入
MonarcHER: A randomized phase II study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer (ABC)
1天前
已完结
Final overall survival (OS) for abemaciclib plus trastuzumab +/- fulvestrant versus trastuzumab plus chemotherapy in patients with HR+, HER2+ advanced breast cancer (monarcHER): A randomized, open-label, phase II trial
1天前
已完结
LBA15 MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC)
1天前
已完结
Tandem mass tag (TMT) quantitative protein analysis-based proteomics and parallel reaction monitoring (PRM) validation revealed that MST4 accelerates osteosarcoma proliferation by increasing MRC2 activity
2天前
已完结
Gastrointestinal adverse effects of cyclin-dependent kinase 4 and 6 inhibitors in breast cancer patients: a systematic review and meta-analysis
1个月前
已完结
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
1个月前
已完结
Dupilumab Treatment Is Associated With ClinicalImprovement and a Shift Toward a Health-Associated Nasal Passage Microbiota in Diffuse Type2 Chronic Rhinosinusitis
1个月前
已完结
Clinical, Epidemiologic, and Pathologic Significance of ERBB2-Low Expression in Breast Cancer
1个月前
已完结
Multiple imputation in survival models: applied on breast cancer data
1个月前
已关闭
Outcomes of Treatment of Cats with Effusive Feline Infectious Peritonitis Using Parenterally Administered Remdesivir with Two Different Maintenance Dose Concentrations
1个月前
已关闭
皖公网安备34019202002308
